Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?
暂无分享,去创建一个
[1] N. Demartines,et al. Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach? , 2022, International journal of molecular sciences.
[2] S. Gallinger,et al. Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases , 2022, JAMA Surgery.
[3] G. Sapisochin,et al. Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time? , 2021, Hepatology.
[4] C. Combescure,et al. Predicting recurrence of hepatocellular carcinoma after liver transplantation using a novel model that incorporates tumor and donor‐related factors , 2021, Transplant international : official journal of the European Society for Organ Transplantation.
[5] Jae Geun Lee,et al. Circulating Cancer Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation , 2021, Gut and liver.
[6] Jia Fan,et al. Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation , 2021, Journal of Cancer.
[7] H. Tseng,et al. Circulating Tumor Cell–Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue‐Based Messenger RNA Profiling Into a Noninvasive Setting , 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[8] A. Goldenberg,et al. The Toronto Postliver Transplantation Hepatocellular Carcinoma Recurrence Calculator: A Machine Learning Approach , 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[9] Wei Liu,et al. Association of phenotypic transformation of circulating tumor cells and early recurrence in patients with hepatocellular carcinoma following liver transplantation. , 2021, Asian journal of surgery.
[10] R. Sebra,et al. Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer , 2021, Gut.
[11] R. Dhanasekaran,et al. Down-staging Outcomes for Hepatocellular Carcinoma: Results from the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. , 2021, Gastroenterology.
[12] M. L. de la Mata,et al. Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation , 2021, Cancers.
[13] N. Demartines,et al. Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone‐Dependent Release of Circulating Tumor DNA , 2021, Hepatology communications.
[14] T. Luedde,et al. Serum levels of circulating microRNA-107 are elevated in patients with early-stage HCC , 2021, PloS one.
[15] N. Demartines,et al. The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication , 2021, Cancers.
[16] Ya Cao,et al. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[17] J. Llovet,et al. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma , 2020, Oncogene.
[18] T. Luedde,et al. Circulating levels of microRNA193a-5p predict outcome in early stage hepatocellular carcinoma , 2020, PloS one.
[19] Amber L. Simpson,et al. Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers , 2020, Cell.
[20] Qiang Zhao,et al. Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation , 2020, Annals of translational medicine.
[21] H. Tseng,et al. Hepatocellular Carcinoma–Circulating Tumor Cells Expressing PD‐L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors , 2020, Hepatology communications.
[22] C. Strassburg,et al. Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[23] L. Mariani,et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. , 2020, The Lancet. Oncology.
[24] Yanwei Luo,et al. High expression of circulating exosomal circAKT3 is associated with higher recurrence in HCC patients undergoing surgical treatment. , 2020, Surgical oncology.
[25] M. Schmelzle,et al. Increased Cell-Free DNA Plasma Concentration Following Liver Transplantation Is Linked to Portal Hepatitis and Inferior Survival , 2020, Journal of clinical medicine.
[26] Namita Srivastava,et al. The Machine‐Learning Approach , 2020, Machine Learning for iOS Developers.
[27] A. Villanueva,et al. Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma , 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[28] Chi-Chih Wang,et al. Circulating exosomal miR‐92b: Its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[29] W. Tak,et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma , 2018, International journal of cancer.
[30] Jing Xu,et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines , 2018, Journal of Extracellular Vesicles.
[31] Boris M. Hartmann,et al. High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma , 2018, Scientific Reports.
[32] B. Naini,et al. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma , 2018, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[33] Yugang Wang,et al. Decreased levels of serum exosomal miR‐638 predict poor prognosis in hepatocellular carcinoma , 2018, Journal of cellular biochemistry.
[34] Jie Zhou,et al. Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation , 2018, Journal of Investigative Medicine.
[35] M. Mahajan,et al. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma , 2018, Oncogene.
[36] Zhiyu Qian,et al. Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation , 2018, Oncology letters.
[37] W. Guo,et al. Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma , 2017, Clinical Cancer Research.
[38] F. Lammert,et al. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. , 2017, Journal of hepatology.
[39] Neil Mehta,et al. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant , 2017, JAMA oncology.
[40] P. Parrilla,et al. Oncological Evaluation by Positron-emission Tomography, Circulating Tumor Cells and Alpha Fetoprotein in Patients With Hepatocellular Carcinoma on the Waiting List for Liver Transplantation. , 2016, Transplantation proceedings.
[41] David Jamieson,et al. Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma? , 2016, Journal of hepatology.
[42] J. Joh,et al. Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria , 2016, Annals of surgery.
[43] Chang Xian Li,et al. Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation , 2016, Oncotarget.
[44] A. Minguela,et al. Comparison of Two Types of Liquid Biopsies in Patients With Hepatocellular Carcinoma Awaiting Orthotopic Liver Transplantation. , 2015, Transplantation Proceedings.
[45] Gary K. Schwartz,et al. Tumour exosome integrins determine organotropic metastasis , 2015, Nature.
[46] J. Dufour,et al. Total tumor volume and alpha‐fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation , 2015, Hepatology.
[47] Xiao-jing Yang,et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. , 2015, The Lancet. Oncology.
[48] T. Tsunoda,et al. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy , 2015, Cellular and molecular gastroenterology and hepatology.
[49] Michael A. Hollingsworth,et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver , 2015, Nature Cell Biology.
[50] A. Villanueva,et al. Liquid biopsy in liver cancer. , 2015, Discovery medicine.
[51] Jessica Zucman-Rossi,et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.
[52] Y. N. Park,et al. Increased Expression of Circulating Cancer Stem Cell Markers During the Perioperative Period Predicts Early Recurrence After Curative Resection of Hepatocellular Carcinoma , 2015, Annals of Surgical Oncology.
[53] K. Mimori,et al. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation , 2015, British Journal of Cancer.
[54] Hiromi Nakamura,et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.
[55] S. Fan,et al. Prediction of Posthepatectomy Recurrence of Hepatocellular Carcinoma by Circulating Cancer Stem Cells: A Prospective Study , 2011, Annals of surgery.
[56] Ruifa Han,et al. Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT , 2011, Hepatitis monthly.
[57] J. Trotter,et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[58] S. Cheung,et al. Albumin mRNA in Plasma Predicts Post-Transplant Recurrence of Patients With Hepatocellular Carcinoma , 2008, Transplantation.
[59] Y. Takeda,et al. Detection of AFP mRNA‐expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation , 2007, Transplant international : official journal of the European Society for Organ Transplantation.
[60] K. Hatakeyama,et al. Comparison between human-telomerase reverse transcriptase mRNA and alpha-fetoprotein mRNA as a predictive value for recurrence of hepatocellular carcinoma in living donor liver transplantation. , 2006, Transplantation proceedings.
[61] M. Plebani,et al. Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. , 2004, Clinica chimica acta; international journal of clinical chemistry.
[62] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[63] Bernard Lacour,et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer , 2004, Hepatology.
[64] L. Ferrell,et al. Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[65] V. Mazzaferro,et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.
[66] J. Guerrero,et al. Detection of p53 Mutations in Circulating DNA of Transplanted Hepatocellular Carcinoma Patients as a Biomarker of Tumor Recurrence. , 2016, Advances in experimental medicine and biology.
[67] L. Mariani,et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. , 2009, The Lancet. Oncology.
[68] J. Manson,et al. Prospective Study of , 2007 .
[69] A. Tannapfel,et al. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma. , 2002, Surgery.
[70] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.